Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Lymphoma

Free Subscription 07.01.2019 5 Br J Haematol 2 Haematologica 1 J Am Acad Dermatol 2 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Br J Haematol

1. BUDDE LE, Wu D, Martin DB, Philip M, et al
   Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
   Br J Haematol. 2018;183:601-607.
   PubMed     Text format     Abstract available
   
   
2. LAVOLE J, Le Goff M, Oudjit A, Sogni P, et al
   Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
   Br J Haematol. 2018;180:629.
   PubMed     Text format    
   
   
3. KALAC M, Lue JK, Lichtenstein E, Turenne I, et al
   Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
   Br J Haematol. 2018;180:757-760.
   PubMed     Text format    
   
   
4. NISHINO M, Ramaiya NH, Hatabu H, Hodi FS, et al
   PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
   Br J Haematol. 2018;180:752-755.
   PubMed     Text format    
   
   
5. DI NAPOLI A, Jain P, Duranti E, Margolskee E, et al
   Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.
   Br J Haematol. 2018;180:741-744.
   PubMed     Text format    
   
   

   
   Haematologica

6. TAYLOR JG, Clear A, Calaminici M, Gribben JG, et al
   Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.
   Haematologica. 2019;104:e42-e44.
   PubMed     Text format    
   
   
7. SASSE S, Reddemann K, Diepstra A, Borchmann S, et al
   Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
   Haematologica. 2019;104:e45-e46.
   PubMed     Text format    
   
   

   
   J Am Acad Dermatol

8. STEINKE S, Zeidler C, Riepe C, Bruland P, et al
   Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.
   J Am Acad Dermatol. 2018;79:457-463.
   PubMed     Text format     Abstract available
   
   

   
   Leukemia

9. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
   Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
   Leukemia. 2018;32:364-375.
   PubMed     Text format     Abstract available
   
   
10. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

11. CRAIG JW, Mina MJ, Crombie JL, LaCasce AS, et al
    Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
    PLoS One. 2018;13:e0199708.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: